{
    "nctId": "NCT03665077",
    "briefTitle": "Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome",
    "officialTitle": "Pilot Trial to Evaluate Blood and Imaging Based Biomarkers for Aromatase Inhibitor Induced Musculoskeletal Syndrome",
    "overallStatus": "COMPLETED",
    "conditions": "Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS), Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 28,
    "primaryOutcomeMeasure": "Oxylipin Levels",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Be capable of understanding the investigational nature of the study and all pertinent aspects of the study\n2. Be capable of signing and providing written consent in accordance with institutional and federal guidelines\n3. Have a histologically-confirmed diagnosis of breast cancer\n4. Be willing and able to comply with scheduled visits, treatment plan, and SWE ultrasound imaging\n5. Age \u2265 21 years\n6. Post-menopausal women with 1st event of ER+ early stage breast cancer (0-3)\n7. Completed definitive therapy (surgery \u00b1 radiation)\n8. Candidates for adjuvant AI therapy\n\nExclusion Criteria:\n\n1. Have received adjuvant or neo-adjuvant chemotherapy\n2. Prior endocrine therapy (AI or tamoxifen)\n3. History of rheumatoid arthritis or other autoimmune arthritis\n4. Daily non-steroidal anti-inflammatory drug (NSAID) use (except for daily aspirin use)\n5. Current use of daily corticosteroids or immunosuppressive therapies",
    "sex": "FEMALE",
    "minimumAge": "21 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}